Breaking Finance News

Medtronic (FRA:MDT) stock price target increased to 85.00EUR, issued a research note today by Stifel

In a report released on Thursday November 23, 2017 Stifel increased the stock price target of Medtronic (FRA:MDT) from 83.00EUR to 85.00EUR indicating a possible upside of 0.06%.

Previously on Wednesday November 22, 2017, Stifel reported on Medtronic (FRA:MDT) increased the target price from 83.00EUR to 85.00EUR. At the time, this indicated a possible upside of 0.06%.

Yesterday Medtronic (FRA:MDT) traded 0.00% even at 80.52EUR. The company’s 50-day moving average is 79.96EUR and its 200-day moving average is 83.33EUR. The last closing price is down -7.68% from the 200-day moving average, compared to the S&P 500 which has increased 0.01% over the same time period. 110 shares of the stock traded hands, down from an average trading volume of 4,928,400

See Chart Below

Medtronic (FRA:MDT)

Medtronic has a 52 week low of 69.35EUR and a 52 week high of 89.72EUR with a P/E ratio of 25.89 The company’s market cap is currently 0 EUR.

In addition to Stifel reporting its stock price target, a total of 22 brokers have issued a research note on the company. The average stock price target is 88.75EUR with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Medtronic (FRA:MDT)

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The companyÂ’s Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions. The companyÂ’s Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The companyÂ’s Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.